IP Library › Granted Patent US 11,167,025
Granted Patent B2
US 11,167,025 · App. 16/554,133 · Granted Nov 9, 2021

Altering the immundominance hierarchy using a DNA vaccine expressing conserved regions

Inventors: George Pavlakis (Rockville, MD); Barbara Felber (Rockville, MD); James Mullins (Seattle, WA)
Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
A61K39/21A61K39/12A61N1/327C07K14/005C12N7/00A61K2039/53A61K2039/545C12N2740/16222C12N2740/16234C12N2740/16271
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,167,025
App. No.
16/554,133
Granted
Nov 9, 2021
Kind
B2
Abstract

The invention provides methods and compositions for eliciting broad immune responses. The methods employ nucleic acid vaccines that encodes highly conserved elements from a virus.

Claims (19)

1. A nucleic acid comprising a nucleotide sequence encoding a fusion polypeptide comprising the conserved element amino acid sequences of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, wherein the conserved elements are separated by alanine-containing peptide linker amino acid sequences.

2. The nucleic acid of claim 1 , wherein the fusion polypeptide comprises the amino acid sequence SEQ ID NO:15.

3. The nucleic acid of claim 2 , comprising the region of the nucleic acid sequence of SEQ ID NO:17 that encodes p24CE1.

4. The nucleic acid of claim 2 , wherein the fusion polypeptide comprises a GM-CSF signal peptide.

5. The nucleic acid of claim 4 , wherein the fusion polypeptide comprises the amino acid sequence of SEQ ID NO:18.

6. The nucleic acid of claim 2 , wherein the fusion polypeptide comprises the amino acid sequence of SEQ ID NO:23 or the amino acid sequence of SEQ ID NO:27.

7. The nucleic acid of claim 1 , wherein the nucleic acid is an RNA molecule.

8. The nucleic acid of claim 1 , wherein the nucleic acid is a DNA molecule.

9. An expression vector comprising the nucleic acid sequence of claim 1 .

10. The expression vector of claim 9 , further comprising a nucleic acid encoding a second fusion polypeptide comprising the conserved element amino acid sequences of SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14 separated by alanine-containing peptide linker amino acid sequences.

11. The expression vector of claim 10 , wherein the second fusion polypeptide comprises the amino acid sequence SEQ ID NO:16.

12. The expression vector of claim 11 , wherein the nucleic acid encoding the second fusion polypeptide comprises the region of the nucleic acid sequence of SEQ ID NO:17 that encodes p24CE2.

13. The expression vector of claim 11 , wherein the second fusion polypeptide comprises a GM-CSF signal peptide.

14. The expression vector of claim 13 , wherein the second fusion polypeptide comprises the amino acid sequence of SEQ ID NO:19.

15. The expression vector of claim 11 , wherein the second fusion polypeptide comprises the amino acid sequence of SEQ ID NO:21 or comprises the amino acid sequence of SEQ ID NO:29.

16. A nucleic acid construct comprising the nucleic acid of claim 1 , and further comprising a nucleic acid encoding a second fusion polypeptide comprising the conserved element amino acid sequences of SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14, wherein the conserved elements are separated by alanine-containing peptide linker amino acid sequences.

17. A nucleic acid construct comprising the nucleic acid of claim 2 , further comprising a nucleic acid encoding a second fusion polypeptide comprising the amino acid sequence of SEQ ID NO:16.

18. The nucleic acid construct of claim 17 , comprising the nucleic acid sequence of SEQ ID NO:17.

19. The nucleic acid construction of claim 17 , wherein the construct is an RNA molecule.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2019
From: PAVLAKIS, GEORGE; FELBER, BARBARA
To: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 050203/0438 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2019
From: MULLINS, JAMES
To: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Reel/Frame 050203/0534 →
Continuity (4)
Division 15235430 · Aug 12, 2016
Continuation 14382281
Provisional Application 61606265 · Mar 2, 2012
Related Publication 20190381166A1 · Dec 19, 2019